Bank of America Raises Johnson & Johnson (NYSE:JNJ) Price Target to $198.00

Johnson & Johnson (NYSE:JNJ) had its price objective hoisted by equities research analysts at Bank of America from $175.00 to $198.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price target indicates a potential upside of 5.04% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. The Goldman Sachs Group upped their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $188.88.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $188.51 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The firm’s fifty day simple moving average is $176.18 and its two-hundred day simple moving average is $162.83. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $189.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently made changes to their positions in the business. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $27,000. Semmax Financial Advisors Inc. increased its stake in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at about $35,000. Highline Wealth Partners LLC increased its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the last quarter. Finally, Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $47,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.